1  

ESC Sessions of Interest,

Satellite Symposia, Poster Sessions

2  

Program at a glance*

Date/ Time Event Location

Saturday 30 Aug 2014

11:00 - 16.00 Poster session 1: PCI Outcomes in the spotlight One-year results of the taxus liberte post-approval study: comparison with the arrive registry

Poster area - Central Village

12.30 - 13.30 Moderated posters: Antiplatelet therapy and clinical outcomes Bleeding rates in patients with acute coronary syndromes: safety profile of prasugrel and clopidogrel in the prospective swiss acs cohort Impact of chronic kidney disease on long-term cardiovascular outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS trial

Moderated poster corner - Central Village

15.30 - 17.00 Satellite symposium: Hypertension care: it’s time to act. The experts talk! Part 1: The Satellite Symposium

Budapest - Village 5

17.00 - 18.00 Official ESC opening ceremony

Sunday 31 Aug 2014

11.00 – 12.30 ESC Guidelines 2014 overview Myocardial revascularization

Barcelona - Central Village

12:40 – 12.57 Young Investigators Awards Abstracts: Bleeding events and anticoagulation management of atrial fibrillation: follow-up data from the PREFER in AF registry

Luxembourg (The Hub) - Central Village

12.45 - 13.45 Satellite symposium: Hypertension care: it’s time to act. Discuss with the experts! Part 2: The Q&A talk show

Budapest - Village 5

12.45 - 13.45 Satellite symposium: Emerging options for patients with atrial fibrillation

Tallinn - Village 9

14:00–15:30 ESC/EACTS GUIDELINES ON MYOCARDIAL REVASCULARIZATION - The Committee for Practice Guidelines

Barcelona - Central Village

14.00 - 18.00 Poster session 3: Atrial fibrillation: miscellaneous Rhythm control strategies in atrial fibrillation: inter-country differences in Europe. Follow-up data from the PREFER in AF registry

Poster area - Central Village

3  

14:00 - 15:30 Rapid Fire Abstracts: High platelet reactivity: mechanisms and clinical implications

Helsinki (The Hub) - Central Village

*See detailed agendas for further information and timings

Date/ Time Event Location

Monday 1 Sept 2013

08.30 – 12.30 Poster session 4: Predicting prognosis and bleeding risk in MI and atrial fibrillation Risk-prediction scores and bleeding events in atrial fibrillation: data from the PREFER in AF registry Blood pressure treatment Fixed-combination olmesartan/amlodipine (OLM/AML) was superior to perindopril + amlodipine (PER/AML) in reducing central systolic blood pressure (CSBP) in hypertensive patients with diabetes

Poster area - Central Village

8:30 – 12:30 Poster session 4: Blood pressure treatment Pos

12.45 - 13.45 Satellite symposium: Meeting the challenges in atrial fibrillation management: the role of new oral anticoagulants

Tallinn - Village 9

12.45 - 13.45 Co-sponsored satellite symposium: Coagulation assessment in patients treated with novel oral anticoagulants: new developments and practical guidance

Prague - Village 3C

14.00 - 18.00 Poster session 5: Acute coronary syndromes: ongoing challenges Clopidogrel vs. prasugrel and ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: An IABP-SHOCK II sub-analysis

Poster area - Central Village

14.00 - 18.00 Poster session 5: Atrial fibrillation – clinical Sociodemographic and cardiovascular status but not anticoagulant choice independently predict quality of life in patients with atrial fibrillation: results from the PREFER in AF registry

Poster area - Central Village

Tuesday 2 Sept 2014

08.30 - 12.30 Poster session 6: Thrombosis: basic mechanisms and clinical management Thrombosis and current management: The current use of direct oral anticoagulants (DOACs) for the treatment of VTE in Europe-PREFER in VTE

Poster area - Central Village

12.45 - 13.45 Hippocratic wisdom: How to use the NOACs and do no harm

Dublin - Village 3

4  

12.45 - 13.45 ACS management 2014: A case based approach according to new guidelines and registries

Sofia - Village 7

*See detailed agendas for further information and timings

Date/ Time Event Location

Tuesday 2 Sept 2014

14.00 - 18.00 Poster session 7: Embolic risks in atrial fibrillation Trends in antithrombotic management of atrial fibrillation after the last update of ESC guidelines: follow-up data from the PREFER in AF registry Comparison of atrial fibrillation patients with and without an initial awareness of rhythm disturbance in the PREFER in AF registry for outcomes and management differences

Poster area - Central Village

14.00 - 18.00 Poster session 7: Anticoagulants and stroke in atrial fibrillation Quality of Life and patient satisfaction data in atrial fibrillation patients stably treated with a VKA vs patients switched from a VKA to NOAC. The PREFER in AF registry

Poster area - Central Village

14.00 - 18.00 Poster session 7: Platelets and antiplatelet therapy: miscellaneous Effects of clopidogrel, prasugrel and ticagrelor on endothelial function and platelet reactivity in patients after percutaneous coronary intervention High and low platelet reactivity on clopidogrel, prasugrel and ticagrelor in acute coronary syndrome patients: insight from a large cohort Effect of dyspnea under ticagrelor on discontinuation and compliance to therapy in acute coronary syndrome patients treated with percutaneous coronary intervention

Poster area - Central Village

16.30 -16.45 Oral abstract session: Venous thromboembolism: what’s new? Venous thromboembolism management in European countries: Baseline characteristics, risk factors, and comorbidity data from the PREFER in VTE Registry

Tbilisi - Village 7

*See detailed agendas for further information and timings

5  

Event Key: ESC sessions of interest

Official ESC event

Satellite symposium

6  

Agendas in detail

Saturday 30 August

Poster session 1: PCI outcomes in the spotlight Poster area - Central Village

Moderated Posters: Antiplatelet therapy and clinical outcomes Moderated poster corner - Central Village

Time Nr Title Speakers

12:47 P149 Bleeding rates in patients with acute coronary syndromes: safety profile of prasugrel and clopidogrel in the prospective swiss acs cohort

Roland KLINGENBERG

(Zurich, CH)

13:04 P151 Impact of chronic kidney disease on long-term cardiovascular outcomes in medically managed patients with acute coronary syndromes: insights from the TRILOGY ACS trial

Chiara MELLONI

(Durham, US)

Satellite symposium: Hypertension care: it’s time to act. Part 1: The experts talk! The Satellite Symposium Budapest - Village 5

Time Title Speaker

15:30 Chairpersons' introduction Josep REDON (Valencia, ES), Anthony HEAGERTY (Manchester, GB)

15:40 Uncontrolled hypertension: the crisis in patient care.

Michel BURNIER (Lausanne, CH)

15:55 Increasing goal rates by optimising clinical work-up.

Luis Miguel RUILOPE (Madrid, ES)

16:15 How to bring stakeholders together – A practical example: the Low Blood Pressure Vienna initiative.

Roland SCHMIEDER (Erlangen, DE), Thomas WEISS (Vienna, AT)

Time Nr Title Speakers

11:00 - 16.00

P722 One-year results of the taxus liberte post-approval study: comparison with the arrive registry

David LEE (Stanford, US)

7  

16:35 The olmesartan family: important tools to improve blood pressure control.

Massimo VOLPE (Rome, IT)

16:50 Summary and meeting close Josep REDON (Valencia, ES), Anthony HEAGERTY (Manchester, GB)

Sunday 31 August

ESC Guidelines 2014 Overview Barcelona – Central Village

Time Title Speakers

11:18 – 11:36

Myocardial revascularization Stephan WINDECKER (Bern, CH), Philippe H KOLH (Liege, BE)

ESC/EACTS GUIDELINES ON MYOCARDIAL REVASCULARIZATION - The Committee for Practice Guidelines Barcelona – Central Village

Time Title Speakers

14:00 Strength of a joint ESC/EACTS Task Force.

P.H. Kolh (Liège, BE)

14:05 Risk assessment and patient information.

V. Falk (Zurich, CH)

14:20 Revascularization in patients with stable coronary artery disease.

A. Kastrati (Munich, DE)

14:45 Revascularization in patients with coronary artery disease and associated conditions. 1904

M. Sousa Uva (Lisbon, PT)

15:05 Antithrombotic therapy in patients undergoing revascularization. 1905

–

J.-P. Collet (Paris, FR)

15:25 Concluding remarks

S. Windecker (Berne, CH)

8  

Young Investigators Awards Session Thrombosis Young Investigators Awards Abstracts Luxembourg (The Hub) - Central Village

Satellite symposium: Hypertension care: it’s time to act. Part 2: Discuss with the experts! The Q&A talk show Budapest - Village 5

Time Title Speakers

12:45 Chairpersons' introduction - Hypertension care: it’s time to act.

Josep REDON (Valencia, ES), Anthony HEAGERTY (Manchester, GB)

13:00 ‘Talk show’ with Q&A and discussions - Hypertension care: it’s time to act.

Michel BURNIER (Lausanne, CH), Luis Miguel RUILOPE (Madrid, ES), Roland SCHMIEDER (Erlangen, DE), Massimo VOLPE (Rome, IT), Thomas WEISS (Vienna, AT)

13:40 Summary and meeting close - Hypertension care: it’s time to act.

Josep REDON (Valencia, ES)

Time Nr Title Speakers

12:40 1792 Bleeding events and anticoagulation management of atrial fibrillation: follow-up data from the PREFER in AF registry

Luis Miguel RINCON (Madrid, ES)

12:57 1793 Warfarin is associated with a net clinical benefit in patients with atrial fibrillation and chronic kidney disease

Anders NISSEN BONDE (Hellerup, DK)

13:15 1794 The impact of thrombus aspiration on mortality in patients treated with primary percutaneous coronary intervention (10,929 patients)

Daniel JONES (London, GB)

13:32 1795 Impact of NSAID treatment on bleeding risk after myocardial infarction in patients treated with different combinations of aspirin, clopidogrel, or vitamin k antagonist - a Nationwide study

Anne-Marie SCHJERNING OLSEN (Hellerup, DK)

9  

Satellite symposium: Emerging options for patients with atrial fibrillation Tallinn - Village 9

Time Title Speakers

12:45 Welcome and introduction - Emerging options for patients with AF.

Jeffrey WEITZ (Hamilton, CA)

12:50 New insights from ENGAGE AF-TIMI 48.

Christian RUFF (Boston, US)

13:05 Future direction of anticoagulation therapy.

Andreas GOETTE (Paderborn, DE)

13:15 Clinical management of treatment with new oral anticoagulants.

Jack ANSELL (Long Branch, US)

13:30 Panel discussion - Emerging options for patients with AF.

13:40 Closing remarks - Emerging options for patients with AF.

John CAMM (London, GB)

Poster Session 3: Atrial fibrillation: miscellaneous Posters area – Central Village

Time Nr Title Speakers

14:00 - 18.00

P2422 Rhythm control strategies in atrial fibrillation: inter-country differences in Europe. Follow-up data from the PREFER in AF registry

Luis Miguel RINCON (Madrid, ES)

Rapid Fire Abstracts: High platelet reactivity: mechanisms and clinical implications Helsinki (The Hub) - Central Village

Time Nr Title Speakers

14:00 1910 Efficacy of prasugrel in resuscitated patients during therapeutic hypothermia after percutaneous coronary intervention for acute myocardial infarction

Andreas SCHAEFER (Hannover, DE)

14:18 1912 Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated by therapeutic hypothermia after cardiac arrest for acute myocardial infarction

Frantisek BEDNAR (Praha, CZ)

14:36 1914 High residual platelet reactivity after clopidogrel 600 mg loading dose and 1 year mortality after drug-eluting stenting for unprotected left main coronary disease

Thibault LHERMUSIER (Toulouse, FR)

14:45 1915 Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary

Thibault LHERMUSIER (Toulouse, FR)

10  

Monday 1 September

Poster Session 4: Predicting prognosis and bleeding risk in MI and atrial fibrillation Posters area – Central Village

Time Nr Title Speakers

08:30 - 12.30

P3225 P3247

Risk-prediction scores and bleeding events in atrial fibrillation: data from the PREFER in AF registry Fixed-combination olmesartan/amlodipine (OLM/AML) was superior to perindopril + amlodipine (PER/AML) in reducing central systolic blood pressure (CSBP) in hypertensive patients with diabetes

Luis Miguel RINCON (Madrid, ES) Luis Miguel RUILOPE (Madrid, ES)

Satellite symposium: Meeting the challenges in atrial fibrillation management: The role of new oral anticoagulants Tallinn - Village 9

Time Title Speakers

12:45 Welcome and introduction - Meeting the challenges in atrial fibrillation management.

Freek VERHEUGT (Amsterdam, NL)

12:50 Balancing the risk of stroke and bleeding in the treatment of patients with atrial fibrillation.

Gregory Y H LIP (Birmingham, GB)

syndrome: comparative effects of prasugrel and ticagrelor

14:54 1916 Patients receiving drug-eluting stents for stable coronary disease in the ADAPT-DES study: Impact of clopidogrel platelet reactivity on clinical outcomes

Dietmar TRENK (Bad Krozingen, DE)

15:03 1917 The effect of acenocoumarol on the antiplatelet effect of clopidogrel

Paul JANSSEN (Nieuwegein, NL)

15:12 1918 New determinant of clopidogrel hypo-responsiveness in patients with dual antiplatelet maintenance therapy

Dong Hyun LEE (Busan, KR)

11  

13:05 Implementing treatment guidelines in clinical practice: insights from the PREFER in AF registry.

Raffaele DE CATERINA (Chieti, IT)

13:20 What does ENGAGE AF-TIMI 48 add to the management of patients with atrial fibrillation.

Robert Patrick GIUGLIANO (Boston, US)

13:35 Panel discussion - Meeting the challenges in atrial fibrillation management.

13:40 Closing remarks - Meeting the challenges in atrial fibrillation management.

Christoph BODE (Freiburg, DE)

Co-sponsored satellite symposium: Coagulation assessment in patients treated with novel oral anticoagulants: new developments and practical guidance Prague - Village 3C

Time Title Speakers

12:45 Introduction - Coagulation assessment in patients treated with novel oral anticoagulants: new developments and practical guidance.

Marc SAMAMA (Paris Cedex 04, FR)

12:50 Measurement of new oral anticoagulants and influence on coagulation assays.

Edelgard LINDHOFF-LAST (Frankfurt Am Main, DE)

13:15 Role of the physician in the prescription and interpretation of laboratory testing in patients treated with new oral anticoagulants.

John EIKELBOOM (Hamilton, CA)

13:40 Conclusion - Coagulation assessment in patients treated with novel oral anticoagulants: new developments and practical guidance.

Marc SAMAMA (Paris Cedex 04, FR)

Poster session 5: Acute coronary syndromes: ongoing challenges Poster area - Central Village

Time Nr Title Speakers

14:00 –

18.00

P4631 Clopidogrel vs. prasugrel and ticagrelor in

patients with acute myocardial infarction

complicated by cardiogenic shock: An IABP-

SHOCK II sub-analysis

Martin ORBAN

(Starnberg, DE)

12  

Poster Session 5: Atrial fibrillation - clinical Posters area – Central Village

Time Nr Title Speakers

14:00 -

18.00

P4398 Sociodemographic and cardiovascular status

but not anticoagulant choice independently

predict quality of life in patients with atrial

fibrillation: results from the PREFER in AF

registry

Liang-Han LING

(Melbourne, AU)

Tuesday 2 September

Poster Session 6: Thrombosis: basic mechanisms and clinical management Posters area – Central Village

Time Nr Title Speaker

08.30 – 12.30

P5559 Thrombosis and coagulation: The current use of direct oral anticoagulants (DOACs) for the treatment of VTE in Europe-PREFER in VTE

Giancarlo AGNELLI (Perugia, IT)

Hippocratic wisdom: How to use the NOACs and do no harm Dublin - Village 3

Time Title Speaker

12:45 Introduction - Hippocratic wisdom: how to use the NOACs and do no harm.

Hein HEIDBUCHEL (Leuven, BE)

12:50 All strokes are not the same: appropriate means of diagnosis.

Carlos MOLINA (Barcelona, ES)

13:00 A deep dive into bleeding events in ENGAGE-AF.

Robert Patrick GIUGLIANO (Boston, US)

13:15 Using flexible dosing to avoid adverse events. Christian RUFF (Boston, US)

13:25 Application of updated ESC practical guide to avoid harm with novel anticoagulants.

Hein HEIDBUCHEL (Leuven, BE)

13:35 Q&A and closing remarks - Hippocratic wisdom: how to use the NOACs and do no harm.

Hein HEIDBUCHEL (Leuven, BE)

13  

ACS management 2014: A case based approach according to new guidelines and registries Sofia – Village 7

Time Topic Speaker

12:45 Introduction - ACS management 2014. J Wouter JUKEMA (Leiden, NL)

12:50 Case 1. ACS/PCI: A patient cases based on latest guidelines.

Petr WIDIMSKY (Prague, CZ)

13:00 Case 2. ACS/PCI: Patient cases based on real world data.

Peter R SINNAEVE (Leuven, BE)

13:10 Latest guidelines on ACS/PCI: what are the key changes?

Petr WIDIMSKY (Prague, CZ)

13:20 New registries on ACS/PCI: how does the real world look like.

Peter R SINNAEVE (Leuven, BE)

13:30 Panel discussion together with audience - ACS management 2014.

Julinda MEHILLI (Munich, DE), J Wouter JUKEMA (Leiden, NL), Jose LOPEZ-SENDON (Madrid, ES)

Poster Session 7: Embolic risks in atrial fibrillation Posters area – Central Village

Poster Session 7: Anticoagulants and stroke in atrial fibrillation Posters area – Central Village

Time Nr Title Speakers

14:00 –

18.00

P6266 Trends in antithrombotic management of atrial

fibrillation after the last update of ESC

guidelines: follow-up data from the PREFER in

AF registry

Luis Miguel RINCON

(Madrid, ES)

14:00 –

18.00

P6268 Comparison of atrial fibrillation patients with

and without an initial awareness of rhythm

disturbance in the PREFER in AF registry for

outcomes and management differences.

Ameet BAKHAI (Barnet,

GB

Time Nr Title Speakers

14:00 – 18.00

P6250 Quality of Life and patient satisfaction data in atrial fibrillation patients stably treated with a VKA vs patients switched from a VKA to NOAC. The PREFER in AF registry.

Raffaele DE CATERINA (Chieti, IT)

14  

Poster session 7: Platelets and antiplatelet therapy: Miscellaneous Poster area - Central Village

Oral abstract session: Venous thromboembolism: what’s new? Tbilisi - Village 7

Time Nr Title Speaker

16.30 – 16:45

6034 Thrombosis and coagulation: Venous thromboembolism management in European countries: Baseline characteristics, risk factors, and comorbidity data from the PREFER in VTE Registry

Alexander T COHEN (London, GB)

Time Nr Title Speaker

14:00 – 18.00

P6494 Effects of clopidogrel, prasugrel and ticagrelor on endothelial function and platelet reactivity in patients after percutaneous coronary intervention

Dimitris TOUSOULIS (Athens, GR)

14:00 – 18.00

P6495 High and low platelet reactivity on clopidogrel, prasugrel and ticagrelor in acute coronary syndrome patients: insight from a large cohort

Jean-Guillaume DILLINGER (Paris, FR)

14:00 – 18.00

P6497 Effect of dyspnea under ticagrelor on discontinuation and compliance to therapy in acute coronary syndrome patients treated with percutaneous coronary intervention

Melanie GAUBERT (Marseille, FR)